BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 17553044)

  • 1. Consecutive use of different biological therapies in the treatment of psoriasis.
    Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
    Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 5. Remission of photosensitivity following treatment of psoriasis vulgaris with tumour necrosis factor inhibitors.
    Viguier M; Jeanmougin M; Begon E; Verola O; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Sep; 157(3):625-7. PubMed ID: 17596163
    [No Abstract]   [Full Text] [Related]  

  • 6. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 7. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
    Moreno-Ramírez D
    Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
    [No Abstract]   [Full Text] [Related]  

  • 8. Commentary on the European S3-guidelines on the systemic treatment of psoriasis.
    Giannetti A
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):368; author reply 368-9. PubMed ID: 20070453
    [No Abstract]   [Full Text] [Related]  

  • 9. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
    Tan X; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
    Downs AM
    Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis.
    Gualdi G; Monari P; Rossi MT; Crotti S; Calzavara-Pinton PG
    Br J Dermatol; 2012 Jun; 166(6):1373-4. PubMed ID: 22212112
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching biologics for psoriasis.
    Ormerod AD
    Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
    Farnsworth NN; George SJ; Hsu S
    Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
    [No Abstract]   [Full Text] [Related]  

  • 14. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab vs. etanercept in psoriasis.
    Downs AM
    Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
    [No Abstract]   [Full Text] [Related]  

  • 16. Etanercept therapy for psoriasis in a patient with numerous comorbidities.
    De Simone C; Carbone A; Caldarola G
    Am J Clin Dermatol; 2010; 11 Suppl 1():49-50. PubMed ID: 20586510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A scientific debate: key clinical questions in the management of psoriasis.
    Stingl G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
    [No Abstract]   [Full Text] [Related]  

  • 19. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept).
    Cecchi R; Bartoli L
    Dermatol Online J; 2006 Dec; 12(7):4. PubMed ID: 17459290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological therapy for psoriasis.
    Clements SE; Abdul-Ghaffar S; Griffiths CE
    Br J Hosp Med (Lond); 2006 Apr; 67(4):184-7. PubMed ID: 16681304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.